

Research Note

SYNTHETIC STUDIES IN THE 6H-[1,2,4] TRIAZINO [3,4-*b*] [1,3,4] THIADIAZINES

M. M. Heravi* and P. Khosrofar

Department of Chemistry, School of Sciences, Ferdowsi University of Mashhad,
Mashhad, Islamic Republic of Iran


Abstract

4-Amino-6-methyl-1,2,4-triazine-3(2H)-thione-5-one (**1**) was condensed with propargyl bromide in the presence of sodium methoxide to afford 3-propargylmercapto-4-amino-6-methyl-1,2,4-triazin-5-one (**2**). Transformation of the latter to 8-dihydro-3-methyl-7-methylene-4-oxo-6H-[1,2,4] triazino [3,4-*b*] [1,3,4] thiadiazine (**3**) was performed under the condition of palladium (II) salt. Ring closure of (**1**) with phenacyl bromide provides the 3-methyl-7-phenyl-4-oxo-6H-[1,2,4]triazino[3,4-*b*] [1,3,4] thiadiazine.


An examination of numerous antitumor agents from both natural and synthetic sources suggests that a common chemical structural pattern of 2-phenyl naphthalene type ring system is necessary for designing a compound of this type. The 2-phenylnaphthalene type ring system could either be carbocyclic or heterocyclic with nitrogen, oxygen and/or sulfur atoms placed at selected positions [1]. *as*-Triazine-3,5-dione(6-azauracil) has proved to possess a broad spectrum of therapeutic effects which include antiviral [2,3], antitumor [4,5] and antifungal activities [6]. Synthesis of [1,2,4]triazino [1,2,4] triazines [7] which provides few examples of condensed *as*-triazines belonging to the antitumor 2-phenylnaphthalene type, has already been reported. Now we wish to report the synthesis of the heterocyclic system, 6H-[1,2,4]triazino[3,4-*b*][1,3,4] thiadiazine which provides another example of condensed *as*-triazine belonging to the 2-phenylnaphthalene type ring system.

4-Amino-6-methyl-1,2,4-triazin-3(2H)-thione-5-one [8] was condensed with propargyl bromide in the presence of sodium methoxide to afford the corresponding 3-propargylmercapto derivative (**2**). Transformation of **2** to **3** could not be undertaken in either aprotic or protic solvents at their refluxing temperature.


We have recently described the use of Pd-salt for implementation of sequential carbometalation anion capture [9-11] and catalyzed intramolecular cyclization and functionalization of acetylenes [12]. Armed with these experiences, compound (**2**) was refluxed with a catalytic amount of PdCl₂(PhCN)₂ [13] in acetonitrile for 6 hrs. After evaporation of solvent, the crude was directly subjected to column chromatography to obtain a crystalline compound as a major product. Most probably Pd-catalyzed cyclization of (**2**) to (**3**) proceeds via a direct attack of -NH₂ to acetylenic bond activated by coordination of palladium (II).



(1)



(2)



(3)

Keywords: Antitumor agents; 2-Phenylnaphthalene; [1,3,4] thiadiazine; [1,2,4] triazino

4-Amino-6-methyl-1,2,4-triazine-3(2H)-thione-5-one (1) was reacted with phenacyl bromide in the presence of sodium carbonate to give a single crystalline product. Mass spectrum showed that condensation and cyclization had occurred. Depending on the mode of dehydration of (4), two tautomers are possible i.e. 3-methyl-7-phenyl-4-oxo-6H-[1,2,4] triazino[3,4-*b*] [1,3,4] thiadiazine (5) and 8-dihydro-3-methyl-7-phenyl-4-oxo[1,2,4]triazino[3,4-*b*][1,3,4] thiadiazine (6). (Scheme 1).

It has been reported that reaction of 2,5,6-triazino-4-mercaptopyrimidine with α -halogenoketones afforded substituted 7H-pyrimido[4,5-*b*][1,4] thiazines [14]. Synthesis of 2-amino-4(3H)-one-6-phenylpyrimido[4,5,6]thiazine from 2,5-diamino-6-mercaptopyrimidone and phenacyl bromide has also been claimed [15, 16]. Formation of these compounds are reminiscent of the formation of (6). Faced with a similar situation we could have come to the same conclusion, that is that the dehydration product was (6) (pathway b, scheme 1). However, after careful examination of ^1H NMR spectrum it became apparent that only 5 (pathway a) is in accord with the data. The proton NMR spectra of the dehydration product showed a vinyl signal at δ 4.65 ppm and there was no evidence for allylic protons.

Experimental Section

The melting points are uncorrected and were obtained by a Kofler Hazbank Richert type 7841 melting point apparatus. IR spectra were obtained on a 4300 Shimadzu


spectrometer. The ^1H NMR spectra were recorded on a Varian 50A spectrometer using TMS as internal reference and mass spectra were scanned on a Varian Mat CH-7 instrument at 70 eV. Propargyl bromide and phenacyl bromide were purchased from Aldrich.

4-Amino-3-propargylmercapto-6-methyl-1,2,4-triazin-5-one (2)

Sodium (0.2 g, 0.009 mol) was dissolved in MeOH (20 ml). Compound 1 was dissolved in this solution. To this stirred solution, propargyl bromide (0.9 ml) (excess) was added dropwise. The reaction mixture was stirred for 2 hrs. The solid was filtered off, washed with water and crystallized from MeOH. Yield 0.8 g, m.p. 189°C, ^1H NMR, δ (d_6 -DMSO) 2.2 (s, 3H, Me), 3 (t, 1H, CH), 3.8 (d, 2H, CH_2), 5.8 (s, 2H, NH_2 , exchanged with D_2O). M^+ , m/e 196, (rel. intensity) 196 (8), 195 (16), 194 (20), 193 (100). IR (KBr disk) $\bar{\nu}$ 3300, 1680, 1600 cm^{-1} .

8-Dihydro-3-methyl-7-methylene-4-oxo-6H-[1,2,4] triazino[3,4-*b*][1,3,4] thiadiazine (3)

Compound 2 (0.4 g; 0.002 mol) was refluxed in acetonitrile (25 ml) containing $\text{PdCl}_2(\text{PhCN})_2$ (0.01 g) for 4 hrs. After evaporation of solvent, the crude was directly subjected to column chromatography. Elution with 95:5, CHCl_3 : MeOH afforded the title compound as a major product. Yield 0.16 g; 40% m.p. 192°C, ^1H NMR δ (d_6 -DMSO) 2.2 (s, 3H, Me), 3.5 (s, 2H, CH_2), 5.55 (d, 1H), 5.85 (d, 1H), 6.8 (s, 1H, NH, exchanged with D_2O). M^+ , $m/$



Scheme 1

e 196, (rel. intensity), 196 (1), 195 (5), 193 (100). IR (KBr disk) $\bar{\nu}$ 3193, 1687, 1610, 1479, 1240 cm^{-1} .

3-Methyl-7-phenyl-4-oxo-6H-[1,2,4]triazino[3,4-b][1,3,4]thiadiazine (5)

Compound 1 (0.8 g; 0.005 mol) was dissolved in a solution of sodium carbonate [sodium carbonate (0.5 g) in water (25 ml)]. To this solution, phenacyl bromide (0.99 g; 0.005 mol) in ethanol (20 ml) was added dropwise. The reaction mixture was stirred at room temperature for 2 hrs. The solid was filtered off and crystallized from water to afford the title compound. Yield 0.7 g; 53%, m.p. 215°C, $^1\text{H NMR}$, δ (d_6 -DMSO) 2.2 (s, 3H, Me), 4.65 (s, 1H, vinyl CH), 5.8 (s, 1H, NH, exchanged with D_2O), 7.5-7.8 (m, 5H, Ph). M+, m/e for $\text{C}_{12}\text{H}_{10}\text{N}_4\text{OS}$, 258 (rel. intensity), 258 (37), 255 (37), 225 (21), 222 (21), 172 (12), 155 (29), 144 (100), 132 (82). IR (KBr disk) $\bar{\nu}$ 3195, 1687, 1541, 1479, 1344, 1078, 966 cm^{-1} .

Acknowledgements

Financial support from the research council of Ferdowsi University of Mashhad, I.R. Iran is gratefully acknowledged. We would like to thank Miss Maryam Shafaie for her kind assistance.

References

1. Cheng, C.C. In *Progress in medicinal chemistry*, Vol 25, pp. 35-83, G.P. Ellis and G.B. Westneds. Elsevier Science Publishers, B.V. (Biomedical Division), (1988).
2. Falke, D. and Rada, B. *Acta Virol*, **14**, 115, (1970).
3. Sidwell, R.W., Dixon, G.J., Sellers, S.M. and Schabel, F.M. *Jr. Appl. Microbiol.*, **16**, 370, (1968).
4. Creasey, W.A., Fink, M.E., Handschumacker, R.E. and Calabresi, P. *Cancer Res.*, **23**, 444, (1963).
5. Walters, T.R., Aur, R.J.A., Hernandez, K., Veetli, T. and Penkel, D. *Cancer*, **29**, 1057, (1963).
6. Malolcsy, G. *Acta Phytopathol.*, **1**, 245, (1966).
7. Heravi, M.M. and Bakavoli, M. *J. Sci., I.R. Iran*, **3** (3,4), 107, (1992).
8. Dornow, A., Menzel, H. and Maix, P. *Chem. Ber.*, **97**, 2173, (1964).
9. Nuss, J.M., Levine, B.H., Rennels, R.A. and Heravi, M.M. *Tetrahedron Lett.*, 5243, (1991).
10. Heravi, M.M. and Bakavoli, M. *Jour. Chem. Soc. Pak.*, **15**, (4), 257, (1993).
11. Heravi, M.M. and Nuss, J.M. *J. Sci. I.R. Iran*, **4**, (3), 194, (1993).
12. Heravi, M.M. and Bakavoli, *J. Chem. Res.*, **11**, 480, (1995).
13. Kharasch, M.S., Seyler, R.C. and Mayo, F.R. *J. Am. Chem. Soc.*, **60**, 882, (1938).
14. Kim, Y.H. and Mautner, H.G. *J. Med. Chem.*, **17**, 369, (1974).
15. Nair, M.G., Boyce, L.H. and Berry, M.A. *J. Org. Chem.*, **46**, 3354, (1981).
16. Hensie, R.N., Lazarus R.A. and Benkovic, S.J. *J. Med. Chem.*, **26**, 559, (1983).